Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab

摘要: Purpose In a previous cohort study, we proposed that responsiveness of metastatic colorectal cancer (mCRC) to anti–epidermal growth factor receptor (EGFR) monoclonal antibodies has genetic basis, being associated with increased EGFR gene copy number (GCN) as measured by fluorescence in situ hybridization (FISH) individual tumors. The present study was aimed at assessing the predictive role GCN, terms clinical outcome, patients treated panitumumab. Patients and Methods mCRC refractory standard therapies were subset from phase III trial panitumumab plus best supportive care (BSC; n = 58) versus BSC alone (n 34) who selected on basis availability tumor samples adequate for FISH. Results panitumumab, mean GCN less than 2.5/nucleus or 40% cells displaying chromosome 7 polysomy within predicted shorter progression-free survival (PFS; P .039 .029, respectiv...